Irinotecan in Treating Patients With Recurrent Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 1998

Study Completion Date

April 30, 2004

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (9)

19104

University of Pennsylvania Cancer Center, Philadelphia

21231

Johns Hopkins Oncology Center, Baltimore

30322

Emory University Hospital - Atlanta, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35294

University of Alabama Comprehensive Cancer Center, Birmingham

48202

Henry Ford Hospital, Detroit

02114

Massachusetts General Hospital Cancer Center, Boston

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

New Approaches to Brain Tumor Therapy Consortium

OTHER

NCT00003301 - Irinotecan in Treating Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter